Journal of Carcinogenesis
Covering Genesis to Therapeutics

Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 8s, https://carcinogenesis.com/

Salivary Biomarkers and Diagnosis of Cancer: A Review

Dr. Neelanjana Majee [1], Dr. Sarita Vikram Singh [2*], Dr. Dhiraj Gangaram Mahajan [3], Dr. Neha Awasthi [4], Dr. Kavya B T [5], Dr. Mahesh D R[6]

[1]Postgraduate Student, Department of Conservative Dentistry and Endodontics, Kalinga Institute of Dental Sciences, KIIT University, Bhubaneswar, Odisha.

[2]Associate Professor, Department of Conservative Dentistry and Endodontics, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Pune, Maharashtra.

[3]Senior Lecturer, Department of Prosthodontics Crown and Bridge, Annasaheb Chudaman Patil Memorial Dental College and Hospital, Dhule, Maharashtra.

[4]Associate Professor, Department of Pediatric & Preventive Dentistry, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh.

[5]Assistant Professor, Department of Oral Medicine and Radiology, Government Dental College and Research Institute, Bangalore, Karnataka.

[6]Professor, Department of Oral Medicine and Radiology, Dayananda Sagar College of Dental Sciences, Shavige Malleshwara Hills, KS Layout, Bangalore, Karnataka

***Corresponding Author:**

Dr. Sarita Vikram Singh

Associate Professor, Department of Conservative Dentistry and Endodontics, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Pune, Maharashtra.

Email id:: sarita.sing@bharatividyapeeth.edu

ABSTRACT

Cancer remains a significant public health concern worldwide, often diagnosed at advanced stages, leading to poor prognosis and high mortality rates. The identification of reliable, non-invasive biomarkers for early detection is critical for improving patient outcomes. This review discusses the current state of salivary biomarkers in the diagnosis of cancer, exploring various molecular markers, their biological relevance, and their potential in clinical application.

Keywords: *Saliva, Oral Cancer, Biomarkers*

How to Cite: Dr. Neelanjana Majee , Dr. Sarita Vikram Singh , Dr. Dhiraj Gangaram Mahajan , Dr. Neha Awasthi , Dr. Kavya B T , Dr. Mahesh D R, (2025) Salivary Biomarkers and Diagnosis of Cancer: A Review, *Journal of Carcinogenesis*, *Vol.24, No.8s*, 758-762

1. INTRODUCTION

Early detection of cancer is vital for successful treatment and improved patient outcomes. Among various cancers, the oral cavity is an area particularly vulnerable to malignancies, with oral squamous cell carcinoma being the most prevalent. Traditional diagnostic approaches, such as biopsies and imaging techniques, can be invasive, time-consuming, and uncomfortable for patients. As a result, there is a growing interest in discovering non-invasive diagnostic methods that can facilitate early detection and monitoring of oral cancer.[1,2]

Saliva, a readily available and easily accessible biological fluid, presents a promising avenue for cancer diagnosis. It is rich in biological molecules, including proteins, nucleic acids, and metabolites, which can reflect the physiological and pathological state of the oral environment. Salivary biomarkers—molecules present in saliva that can indicate the presence of disease—have shown significant potential in the identification of cancer. The ability to analyze these biomarkers can revolutionize cancer diagnostics, making it possible to diagnose malignancies earlier and with greater accuracy via simple saliva tests.[3,4]

This review explores the current landscape of salivary biomarkers in cancer diagnosis, specifically focusing on their.

advantages, types, methodologies, and clinical applications. By leveraging advances in analytical technologies, researchers aim to develop practical, non-invasive solutions that enhance early detection and patient management in oral cancer and potentially other malignancies. The promise of salivary biomarkers may not only transform clinical practices but also contribute to reduced morbidity and mortality associated with late-stage cancer diagnoses

Biomarkers: Biomarkers, or biological markers, are measurable indicators of biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. They can be found in various biological samples, including blood, urine, tissue, and saliva, and can be proteins, genes, metabolites, or other molecules. Biomarkers play a crucial role in understanding health conditions, enabling early diagnosis, determining disease progression, and guiding treatment decisions.[5,6]

Role of Biomarkers: Biomarkers serve several important roles in medicine, particularly in the fields of oncology, cardiology, and neurology. Their primary functions include:

Early Detection: Biomarkers can help identify diseases at an early stage, even before symptoms manifest, enhancing the chances of successful treatment.

Diagnosis: They assist in confirming the presence of specific diseases, allowing for more accurate and timely diagnoses.

Prognosis: Biomarkers can provide information about the likely course of a disease, helping healthcare providers to predict its progression and possible outcomes.

Treatment Selection: Certain biomarkers guide the choice of therapeutic strategies, particularly in precision medicine, where treatments are tailored to individual patients based on their biomarker profiles.

Monitoring Response: Biomarkers can be used to assess how well a treatment is working and whether adjustments are needed.

Types of Biomarkers: Biomarkers are categorized based on their specific purposes in clinical practice, including predictive, diagnostic, and prognostic biomarkers:

Predictive Biomarkers: Predictive biomarkers indicate the likelihood of a patient's response to a particular treatment or therapy. They help identify which patients will benefit from specific therapeutic agents.

Example: In oncology, the presence of certain genetic mutations, such as EGFR mutations in non-small cell lung cancer, can predict responsiveness to targeted therapies like tyrosine kinase inhibitors.

Diagnostic Biomarkers: Diagnostic biomarkers are used to detect the presence of a specific disease or condition. They help distinguish between disease and non-disease states.

Example: Prostate-specific antigen (PSA) is a well-known diagnostic biomarker used to screen for prostate cancer; elevated levels can indicate the presence of cancer but may require further investigation.

Prognostic Biomarkers: Prognostic biomarkers provide information about the likely outcome or course of a disease, regardless of treatment. They help identify patients at higher risk for adverse outcomes.

Example: In breast cancer, the presence of hormone receptors (such as estrogen and progesterone receptors) can indicate a more favorable prognosis and help guide treatment decisions.

Saliva as Diagnostic Tool: Saliva, often referred to as a mirror of our blood, serves as a valuable diagnostic fluid due to its chemical components that closely resemble those found in blood. Recent advancements in technologies, such as genomics, proteomics, transcriptomics, and microfluidics, have expanded the applications of saliva beyond basic oral health assessments, leading to significant interest in its use for diagnostics in various medical fields.

The advantages of using saliva for diagnostic purposes are numerous: it is non-invasive, easy to collect, and cost-effective. Salivary sampling requires no specialized medical personnel, allowing for real-time diagnostic values and multiple samples to be collected effortlessly. Furthermore, patients can collect samples at home, minimizing cross-contamination risks. Overall, saliva presents a less expensive alternative to serum for sampling, transportation, and storage, involving less manipulation during diagnostic processes. These benefits make saliva an attractive option for screening tests and broader diagnostic applications.[7,8]

Salivary Biomarkers in Cancer: Genome, Epigenome, Transcriptome, Proteome, Metabolome, and Microbiota: The landscape of cancer diagnostics is evolving, with increasing focus on non-invasive methods for early detection and monitoring. Saliva, as a diagnostic medium, offers a wealth of biological information that can be analyzed to identify salivary biomarkers related to cancer. Among these are distinct molecular profiles from the genome, epigenome, transcriptome, proteome, metabolome, and microbiota. Each of these components contributes to our understanding of cancer biology and presents opportunities for novel diagnostic and prognostic tools.[9,10]

Genome: The human genome contains the complete genetic information necessary for growth, development, and function. In the context of cancer, specific genetic alterations such as mutations, copy number variations, and chromosomal

rearrangements can be detected in salivary samples.

Salivary DNA: Fragments of circulating tumor DNA (ctDNA) can be harvested from saliva and analyzed for mutations associated with various cancers. For instance, studies have identified mutated oncogenes and tumor suppressor genes, which offer insights into tumorigenesis and aid in early cancer detection.

Epigenome: The epigenome refers to the chemical modifications of DNA and histones that regulate gene expression without altering the underlying DNA sequence. These modifications influence cellular behavior and play a significant role in cancer development.

Methylation Patterns: Abnormal DNA methylation patterns can be indicative of cancer. Salivary analysis has revealed specific methylation markers associated with oral squamous cell carcinoma (OSCC) and other malignancies. Detecting these changes in saliva could allow for non-invasive cancer screening and risk assessment.

Transcriptome: The transcriptome encompasses all RNA molecules expressed in a cell at a given time, reflecting gene activity.

mRNA and Non-coding RNAs: Saliva contains various messenger RNAs (mRNAs) and non-coding RNAs, such as microRNAs (miRNAs) that can be associated with cancer. For example, specific miRNAs linked to oral cancer have been found to be differentially expressed in saliva, providing potential biomarkers for diagnosis and prognosis. Their roles in regulating tumor-related pathways make them attractive candidates for understanding cancer biology.

Proteome: The proteome refers to the entire set of proteins expressed by a genome under specific conditions.

Salivary Proteins: Analyzing the proteome of saliva can reveal alterations in protein composition related to cancer. Salivary proteins such as cytokines, enzymes, and structural proteins can serve as indicators of malignancy. For instance, elevated levels of inflammatory cytokines have been associated with oral cancer, while proteins such as MMP-9 are linked to tumor progression and metastasis.

Metabolome: The metabolome is the complete set of metabolites present in a biological system, reflecting metabolic activity.

Metabolomic Profiling: Saliva is rich in metabolic byproducts, and profiling these metabolites can provide valuable insights into cancer metabolism. Changes in salivary metabolites, such as amino acids and fatty acids, have been associated with tumor presence and progression. For example, specific metabolic signatures found in saliva have been linked to oral squamous cell carcinoma, helping in early detection.

Microbiota: The oral microbiota consists of the diverse community of microorganisms residing in the oral cavity, including bacteria, viruses, and fungi.

Microbial Dysbiosis: Changes in the composition of oral microbiota have been associated with various cancers, including oral cancer. Certain bacterial species have been implicated in promoting carcinogenesis through inflammatory responses or direct interactions with host cells. Analyzing salivary microbiota profiles could offer insights into the link between oral health and cancer risk, providing a new dimension for predictive diagnostics.

Salivary Biomarkers in Oral Cancer: Oral cancer, particularly oral squamous cell carcinoma (OSCC), represents a significant global health challenge. Saliva offers a promising non-invasive medium for the early detection and monitoring of this disease.[10,11]

Key Biomarkers:

MicroRNAs: Studies have identified specific miRNAs, such as miR-21 and miR-155, that are consistently upregulated in the saliva of patients with OSCC. These miRNAs are involved in tumorigenesis and can serve as biomarkers for diagnostic and prognostic purposes.

Cytokines: Salivary levels of pro-inflammatory cytokines like IL-6 and IL-8 have been associated with OSCC. Elevated levels of these markers indicate inflammation and may correlate with tumor size and stage.

Proteins: Other salivary proteins, such as MMP-9, are implicated in tissue remodeling and metastasis and can be indicative of disease progression.

Salivary Biomarkers in Breast Cancer: Breast cancer is one of the most common cancers among women, and salivary diagnostics are being explored to provide insights into its diagnosis and management.[12]

Key Biomarkers:

MicroRNAs: Salivary miRNA profiles in breast cancer patients may reveal dysregulation of specific miRNAs, including miR-10b and miR-125b, which can aid in early diagnosis and assessment of treatment efficacy.

Circulating Tumor DNA (ctDNA): Studies have shown that tumor-derived DNA can be detected in saliva, providing a non-invasive method for identifying genetic mutations associated with breast cancer.

Protein Markers: Elevated levels of proteins such as Her-2/neu are often found in the saliva of breast cancer patients, reflecting tumor activity and aiding in therapeutic decision-making.

Salivary Biomarkers in Lung Cancer: Lung cancer is a leading cause of cancer-related deaths globally, making early detection critical. Salivary biomarkers have potential as a diagnostic tool.[10,13]

Key Biomarkers:

MicroRNAs: Specific salivary miRNAs like miR-21 and miR-155 have been found to be significantly dysregulated in lung cancer, suggesting their utility as diagnostic and prognostic biomarkers.

Proteins: Increased salivary levels of proteins, such as CEA (carcinoembryonic antigen) and CYFRA 21-1, have been correlated with lung cancer presence and can aid in diagnosis.

Volatile Organic Compounds (VOCs): Unique profiles of VOCs in saliva may differentiate lung cancer patients from healthy individuals, representing a novel diagnostic approach.

Salivary Biomarkers in Pancreatic Cancer: Pancreatic cancer is one of the most aggressive forms of cancer, and early detection is crucial for improving patient outcomes. Salivary biomarkers are being investigated for their potential in this challenging field.[14]

Key Biomarkers:

MicroRNAs: Several studies have identified specific miRNAs, such as miR-10b and miR-21, which are upregulated in the saliva of pancreatic cancer patients compared to healthy controls.

Proteins: Saliva may exhibit altered levels of proteins associated with pancreatic cancer, such as CA 19-9, a well-known serum marker that can also be analyzed in saliva.

Metabolites: Metabolomic profiling of saliva has shown changes in various metabolites that might reflect pancreatic cancer metabolism, offering insights into potential diagnostic markers.

Future Prospective of Salivary Biomarkers: Salivary biomarkers hold great promise for enhancing cancer diagnosis in the future. Non-invasive and easily accessible, saliva can provide crucial insights into the metabolic and genetic changes associated with cancer. Advances in molecular techniques, such as genomics and proteomics, will improve the identification of specific biomarkers linked to various cancers. Moreover, integrating salivary diagnostics with artificial intelligence can enhance accuracy and predictive power. This approach may enable earlier detection, personalized treatment strategies, and improved patient outcomes, making salivary biomarkers a vital tool in oncology.

2. CONCLUSION:

Salivary biomarkers present a promising avenue for the non-invasive diagnosis and monitoring of various cancers, including oral, breast, lung, and pancreatic cancer. Ongoing research is essential for validating these biomarkers and integrating them into clinical practice. The ability to utilize saliva for cancer detection not only offers convenience and accessibility but also holds the potential for improving patient outcomes through early intervention and personalized treatment strategies. As the field advances, salivary diagnostics may significantly enhance cancer care and management.

REFERENCES

[1] Chacko N, Ankri R. Non-invasive early-stage cancer detection: current methods and future perspectives. Clin Exp Med. 2024 Dec 21;25(1):17.

[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

[3] Ghosh AK, Nath A, Elangovan E, Banerjee A, Ramalingam K, Sethuraman S. Exploring Salivary Biomarkers for Tumor Diagnosis: A Narrative Review. Cureus. 2024 Jul 30;16(7):e65725.

[4] Lee JM, Garon E, Wong DT. Salivary diagnostics. Orthod Craniofac Res. 2009 Aug;12(3):206-11.

[5] Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in Cancer Detection, Diagnosis, and Prognosis. Sensors (Basel). 2023 Dec 20;24(1):37.

[6] Freidlin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: Design issues. J. Natl. Cancer Inst. 2010;102:152–160.

[7] Albagieh H, Alshehri AZ, Alduraywishi AS, Aldaws A, AlBalawi SS, Abu Shaqqaf HF, Almubayi RA. Evaluation of Salivary Diagnostics: Applications, Benefits, Challenges, and Future Prospects in Dental and Systemic Disease Detection. Cureus. 2025 Jan 16;17(1):e77520.

[8] Segal A, Wong DT. Salivary diagnostics: enhancing disease detection and making medicine better. Eur J Dent

Educ. 2008 Feb;12 Suppl 1(Suppl 1):22-9.

[9] Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Med Oncol. 2017 Jan;34(1):7.

[10] Swaathi R, Narayan M, Krishnan R. Salivary biomarkers in cancer - A narrative review. Oral Oncology Reports. 2024;10:100503

[11] Nguyen TTH, Sodnom-Ish B, Choi SW, Jung HI, Cho J, Hwang I, Kim SM. Salivary biomarkers in oral squamous cell carcinoma. J Korean Assoc Oral Maxillofac Surg. 2020 Oct 31;46(5):301-312.

[12] Koopaie M, Kolahdooz S, Fatahzadeh M, Manifar S. Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta-analysis. Cancer Med. 2022 Jul;11(13):2644-2661.

[13] Skallevold HE, Vallenari EM, Sapkota D. Salivary Biomarkers in Lung Cancer. Mediators Inflamm. 2021 Oct 13;2021:6019791

[14] Al Balushi H, Chowdhury P, Babu HM, Rehman A, Bokhari SFH, Al-Tarawneh LM, Al-Adwan AJ, Cheran M, Chilla SP, Addula AR, Amir M. The Potential of Salivary Biomarkers in Early Detection of Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cureus. 2024 Feb 26;16(2):e55003.